These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21652542)

  • 1. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma.
    Preis M; Gardner TB; Gordon SR; Pipas JM; Mackenzie TA; Klein EE; Longnecker DS; Gutmann EJ; Sempere LF; Korc M
    Clin Cancer Res; 2011 Sep; 17(17):5812-21. PubMed ID: 21652542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-10b inhibits migration and invasion of pancreatic ductal adenocarcinoma via regulating E2F7.
    Xu C; Qi X
    J Clin Lab Anal; 2020 Oct; 34(10):e23442. PubMed ID: 32592206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
    Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
    Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
    Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis.
    Nakata K; Ohuchida K; Mizumoto K; Kayashima T; Ikenaga N; Sakai H; Lin C; Fujita H; Otsuka T; Aishima S; Nagai E; Oda Y; Tanaka M
    Surgery; 2011 Nov; 150(5):916-22. PubMed ID: 22018284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis.
    Kadera BE; Li L; Toste PA; Wu N; Adams C; Dawson DW; Donahue TR
    PLoS One; 2013; 8(8):e71978. PubMed ID: 23991015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
    Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
    PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. microRNA-10b: a new marker or the marker of pancreatic ductal adenocarcinoma?
    Setoyama T; Zhang X; Natsugoe S; Calin GA
    Clin Cancer Res; 2011 Sep; 17(17):5527-9. PubMed ID: 21816909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression.
    Cheng RF; Wang J; Zhang JY; Sun L; Zhao YR; Qiu ZQ; Sun BC; Sun Y
    Chin J Cancer; 2016 Jul; 35(1):64. PubMed ID: 27371108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions.
    du Rieu MC; Torrisani J; Selves J; Al Saati T; Souque A; Dufresne M; Tsongalis GJ; Suriawinata AA; Carrère N; Buscail L; Cordelier P
    Clin Chem; 2010 Apr; 56(4):603-12. PubMed ID: 20093556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
    Jamieson NB; Morran DC; Morton JP; Ali A; Dickson EJ; Carter CR; Sansom OJ; Evans TR; McKay CJ; Oien KA
    Clin Cancer Res; 2012 Jan; 18(2):534-45. PubMed ID: 22114136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas.
    Permuth-Wey J; Chen YA; Fisher K; McCarthy S; Qu X; Lloyd MC; Kasprzak A; Fournier M; Williams VL; Ghia KM; Yoder SJ; Hall L; Georgeades C; Olaoye F; Husain K; Springett GM; Chen DT; Yeatman T; Centeno BA; Klapman J; Coppola D; Malafa M
    PLoS One; 2015; 10(1):e0116869. PubMed ID: 25607660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.
    Kent OA; Mullendore M; Wentzel EA; López-Romero P; Tan AC; Alvarez H; West K; Ochs MF; Hidalgo M; Arking DE; Maitra A; Mendell JT
    Cancer Biol Ther; 2009 Nov; 8(21):2013-24. PubMed ID: 20037478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma.
    Wu Z; Zhou L; Ding G; Cao L
    Cancer Biomark; 2017; 18(1):35-39. PubMed ID: 27814273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer.
    Giovannetti E; van der Velde A; Funel N; Vasile E; Perrone V; Leon LG; De Lio N; Avan A; Caponi S; Pollina LE; Gallá V; Sudo H; Falcone A; Campani D; Boggi U; Peters GJ
    PLoS One; 2012; 7(11):e49145. PubMed ID: 23155457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma.
    Bai Z; Sun J; Wang X; Wang H; Pei H; Zhang Z
    Oncol Rep; 2015 Aug; 34(2):595-602. PubMed ID: 26062664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
    Cote GA; Gore AJ; McElyea SD; Heathers LE; Xu H; Sherman S; Korc M
    Am J Gastroenterol; 2014 Dec; 109(12):1942-52. PubMed ID: 25350767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
    Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of selected microRNAs in pancreatic ductal adenocarcinoma: is there a relation to tumor morphology, progression and patient's outcome?
    Szabo A; Gurlich R; Liberko M; Soumarova R; Vernerova Z; Mandys V; Popov A
    Neoplasma; 2020 Sep; 67(5):1170-1181. PubMed ID: 32567937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.